Physician profile
Jeevan Joseph
NPI 1295182731
$4,116.94
in general payments reported to CMS, 2019-2025
33 companies · $608 in 2025
The $608 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $36.55 · 2021: $55.21 · 2022: $802 · 2023: $1,131 · 2024: $1,212 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $874.91 | 2022-2025 | |
| Lilly USA, LLC | $512.03 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $463.98 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $386.36 | 2022-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $334.23 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.11 | 2019-2025 | Jardiance |
| Pfizer INC. | $135.00 | 2022-2025 | |
| Exact Sciences Corporation | $117.96 | 2023-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $115.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.24 | 2023-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $98.83 | 2022-2025 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $89.28 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $72.14 | 2023-2025 | Auvelity |
| Gilead Sciences, INC. | $66.12 | 2023-2024 | |
| Glaxosmithkline, LLC. | $65.47 | 2020-2025 | Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $60.70 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $49.99 | 2024 | Gvoke Hypopen, Recorlev |
| Corium, LLC | $49.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.18 | 2024-2025 | |
| Dexcom, INC. | $35.65 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $27.07 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.47 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.80 | 2022 | |
| Almatica Pharma LLC | $22.91 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $19.43 | 2022 | |
| Teleflex LLC | $16.82 | 2024 | Urolift |
| Daiichi Sankyo INC. | $16.19 | 2022 | |
| Merck Sharp & Dohme LLC | $15.58 | 2023 | M-M-R II, Vaqta, Vaxelis |
| Abiomed | $15.06 | 2024 | Impella |
| Cranial Technologies, INC | $14.36 | 2025 | Doc Band |
| Idorsia Pharmaceuticals US INC | $13.38 | 2023 | Quviviq |
| Seqirus USA INC | $12.86 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Dynavax Technologies Corporation | $11.78 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeevan Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.